Lurasidone, a antipsychotics with potent 5-HT1A antagonistic activity, has been shown to improve the learning and memory deficits induced by MK-801 in rats (Ishiyama et al., 2007; Horisawa et al., 2011) and to improve the cognitive impairment in schizophrenia in the clinic (Samalin et al., 2014; Meltzer et al., 2020). The gene discussed is HTR1A; the disease is Cognitive impairment.